Inherited heart diseases pose unique challenges due to their genetic origins, often affecting multiple family members across generations. Conditions such as Marfan syndrome, long QT syndrome, and dilated cardiomyopathy are caused by mutations in specific genes, leading to structural or electrical abnormalities in the heart. As these diseases may remain asymptomatic for years, genetic testing plays a crucial role in early diagnosis, allowing for proactive management to prevent complications like heart failure or arrhythmias. Treatment approaches are highly individualized, ranging from medication and lifestyle modifications to advanced interventions such as implantable devices. Research into gene therapy and other cutting-edge treatments continues to offer hope for those with genetic and inherited heart diseases, promising improved quality of life and better long-term outcomes.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States